Dennis Ding
Stock Analyst at Jefferies
(2.10)
# 3,179
Out of 5,182 analysts
16
Total ratings
41.67%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Assumes: Buy | $43 → $40 | $15.25 | +162.30% | 1 | Mar 19, 2026 | |
| SGP SpyGlass Pharma | Initiates: Buy | $62 | $21.07 | +194.26% | 1 | Mar 3, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.47 | +0.21% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $27.75 | -27.93% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $28.31 | -8.16% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $38.41 | +43.19% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.76 | +354.55% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $28.53 | +22.68% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.46 | +56.95% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $3.19 | +88.09% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $41.69 | -47.23% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $33.91 | -29.22% | 1 | Dec 19, 2022 |
Olema Pharmaceuticals
Mar 19, 2026
Assumes: Buy
Price Target: $43 → $40
Current: $15.25
Upside: +162.30%
SpyGlass Pharma
Mar 3, 2026
Initiates: Buy
Price Target: $62
Current: $21.07
Upside: +194.26%
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.47
Upside: +0.21%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $27.75
Upside: -27.93%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $28.31
Upside: -8.16%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $38.41
Upside: +43.19%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $28.53
Upside: +22.68%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.46
Upside: +56.95%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $3.19
Upside: +88.09%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $41.69
Upside: -47.23%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $33.91
Upside: -29.22%